Indication
ROS1 positive non-small cell lung cancer
ROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene. Read more about ROS1 positive non-small cell lung cancer
6 drugs 6 manufacturers
Drugs that treat it
Common ROS1 positive non-small cell lung cancer therapies.
ROZLYTREK (entrectinib)
XALKORI (crizotinib)
AUGTYRO (repotrectinib)
IBTROZI (taletrectinib adipate)
JIDEYTRO (zidesamtinib)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene.
These oncogenic fusions result in constitutively active chimeric kinase signaling that drives unchecked cellular proliferation and survival in pulmonary tissues.
This subtype typically presents as non-squamous non-small cell lung cancer, most commonly adenocarcinoma, and predominantly affects a demographic of younger individuals and patients with a light or never-smoking history.
Clinically, it frequently presents at an advanced or metastatic stage with a notable predilection for central nervous system involvement.
- nih.gov
ROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene This subtype typically presents as non-squamous non-small cell lung cancer, most commonly adenocarcinoma, and predominantly affects a demographic of younger individuals and patients with a light or never-smoking history Clinically, it frequently presents at an advanced or metastatic stage w...
- healthline.com
ROS1-positive non-small cell lung cancer is a distinct molecular subtype of epithelial lung malignancy characterized by chromosomal rearrangements or fusions involving the *ROS1* receptor tyrosine kinase gene These oncogenic fusions result in constitutively active chimeric kinase signaling that drives unchecked cellular proliferation and survival in pulmonary tissues
- cancersupportcommunity.org
These oncogenic fusions result in constitutively active chimeric kinase signaling that drives unchecked cellular proliferation and survival in pulmonary tissues This subtype typically presents as non-squamous non-small cell lung cancer, most commonly adenocarcinoma, and predominantly affects a demographic of younger individuals and patients with a light or never-smoking history
- nih.gov
Clinically, it frequently presents at an advanced or metastatic stage with a notable predilection for central nervous system involvement
Personalize your experience
Follow ROS1 positive non-small cell lung cancer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.